Abstract:Rejection of solid organ transplant and graft versus host disease (GvHD) continue to be challenging in post transplantation management. The introduction of calcineurin inhibitors dramatically improved recipients' short-term prognosis. However, long-term clinical outlook remains poor, moreover, the lifelong dependency on these toxic drugs leads to chronic deterioration of graft function, in particular the renal function, infections and de-novo malignancies. These observations led investigators to identify alternative therapeutic options to promote long-term graft survival, which could be used concomitantly, but preferably, replace pharmacologic immunosuppression as standard of care. Adoptive T cell (ATC) therapy has evolved as one of the most promising approaches in regenerative medicine in the recent years. A range of cell types with disparate immunoregulatory and regenerative properties are actively being investigated as potential therapeutic agents for specific transplant rejection, autoimmunity or injury-related indications. A significant body of data from preclinical models pointed to efficacy of cellular therapies. Significantly, early clinical trial observations have confirmed safety and tolerability, and yielded promising data in support of efficacy of the cellular therapeutics. The first class of these therapeutic agents commonly referred to as advanced therapy medicinal products have been approved and are now available for clinical use. Specifically, clinical trials have supported the utility of CD4 + CD25+FOXP3+ regulatory T cells (Tregs) to minimize unwanted or overshooting immune responses and reduce the level of pharmacological immunosuppression in transplant recipients. Tregs are recognized as the principal orchestrators of maintaining peripheral tolerance, thereby blocking excessive immune responses and prevent autoimmunity. Here, we summarize rationale for the adoptive Treg therapy, challenges in manufacturing and clinical experiences with this novel living drug and outline future perspectives of its use in transplantation.

Treg cell-based therapies: challenges and perspectives

Current status and perspectives of regulatory T cell-based therapy

Treg cell therapy: How cell heterogeneity can make the difference

Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective

Therapy with regulatory T-cell infusion in autoimmune diseases and organ transplantation: A review of the strengths and limitations

T Regulatory Cells As an Immunotherapy for Transplantation

Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges

T regulatory cells as an immunotherapy for transplantation.

The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology

From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases

Treg Enhancing Therapies to Treat Autoimmune Diseases

Harnessing regulatory T cells to establish immune tolerance

Chimeric antigen receptor Treg therapy in transplantation

Induced Regulatory T Cells as Immunotherapy in Allotransplantation and Autoimmunity: Challenges and Opportunities

Regulatory T-Cell Therapy for Graft-versus-host Disease.

CAR T cells for treating autoimmune diseases

Potential Application of T-Follicular Regulatory Cell Therapy in Transplantation

The impact of regulatory T cells on the graft-versus-leukemia effect

Tregs in transplantation tolerance: role and therapeutic potential

Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders – Advances and challenges

Conventional T cell therapies pave the way for novel Treg therapeutics